Soma Das

Soma Das

Auto-generated profile, based on publicly available information

Soma Das

Department of Biochemistry, Indian Institute of Science, Bangalore, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HSHetal Abhay Shah
Hetal Abhay Shah
DSDhananjaya Saranath
Dhananjaya Saranath
SDSoma Das
Soma Das
PKPrashant S. Kharkar
Prashant S. Kharkar
AKAnjali Karande
Anjali Karande

29 April 2024 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SDSoma Das
Soma Das
PBPadmanava Behera
Padmanava Behera
DSDipeshwari J Shewale
Dipeshwari J Shewale
JBJanhavi Bodele
Janhavi Bodele
SDSaumitra Das
Saumitra Das
AKAnjali A Karande
Anjali A Karande

7 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSoma Das
Soma Das
PBPadmanava Behera
Padmanava Behera
DSDipeshwari J Shewale
Dipeshwari J Shewale
JBJanhavi Bodele
Janhavi Bodele
SDSaumitra Das
Saumitra Das
AKAnjali A Karande
Anjali A Karande
Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis. The use of neutralizing antibodies could be a more effective therapeutic option. Previously we reported the discovery of a novel epitope at the C terminus of HCV-E2 protein, that induced potent neutralizing antibodies in the infected patients. Furthermore, monoclonal antibodies generated against this epitope could also significantly reduce virus replication in a cell culture system. In this study, we have focused on the generation of single chain variable fragments of this unique neutralizing monoclonal antibody A8A11 raised against the conserved epitope. The nucleotide sequence of the neutralizing monoclonal antibody A8A11 was determined and the scFv gene was constructed followed by cloning into the expression plasmid for recombinant protein expression. The scFv mimicked the antibody in binding to the hepatitis C virus like particles (HCV-LP). As expected, the scFv inhibited HCV-LP binding to hepatocytes and could effectively reduce viral replication in the cell culture system. More importantly, scFv A8A11 could restrict serum HCV RNA levels in HCV-infected chimeric mice harboring human hepatocytes. Results provide a basis for developing a promising scFv-based entry inhibitor, which could be more effective against viruses refractory to drugs targeting viral enzymes.